SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. GOOGL
6. ABBV
7. DFTX
8. USO
9. APGE
10. HOOD

Go back to SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus

AstraZeneca Q1 preview: In-line quarter expected as pipeline catalysts take center stage

April 28, 2026 4:00 PM EDT

AstraZeneca (NASDAQ: AZN) reports first-quarter results on Wednesday, with analysts expecting a solid but unexciting print, as investor focus shifts firmly toward a busy second-half pipeline newsflow that Bank of America says could drive a meaningful re-rating of the stock.

BofA analyst Sachin Jain said in a preview note released at the start of April... More